Skip to main content
    N

    Novo Nordisk A/S (NVO)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $39.24
    +1.12 (+2.94%)

    Market Cap: $167.96B

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    77%(30/39)
    Avg Surprise
    +4.34%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$4.83
    Range$4.01 - $5.33
    4 analysts
    EPS Revisions
    1
    0
    7d
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$4.66+3.7%
    60d ago$5.13-6.0%
    30d ago$5.11-5.6%
    7d ago$5.00-3.6%
    Current$4.83
    Revenue Consensus
    $73.2B
    Range$71.1B - $76.0B
    11 analysts
    Period ending Dec 31, 2026
    EPS Consensus$5.76
    Range$4.24 - $7.48
    8 analysts
    Revenue Consensus
    $84.3B
    Range$56.5B - $117.7B
    27 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$5.76---
    Sep 26EST
    		-$4.83---
    Jun 26
    Reported Aug 5
    		$0.96$0.82+17.07%Beat-83.9%
    Mar 26
    Reported May 6
    		$6.63$6.96-4.74%Miss+1.5%
    Dec 25
    Reported Feb 3
    		$6.04$5.90+2.37%Beat-4.7%
    Sep 25
    Reported Nov 5
    		$1.02$0.77+32.47%Beat-83.3%
    Jun 25
    Reported Aug 6
    		$5.96$6.00-0.67%Miss+803.0%
    Mar 25
    Reported May 7
    		$6.53$6.07+7.58%Beat+686.7%
    Dec 24
    Reported Feb 5
    		$6.34$5.97+6.20%Beat+793.0%
    Sep 24
    Reported Nov 6
    		$6.12$5.92+3.38%Beat+738.4%
    Jun 24
    Reported Aug 7
    		$0.66$0.74-10.40%Miss-1.5%
    Mar 24
    Reported May 2
    		$0.83$0.77+7.79%Beat+31.7%
    Dec 23
    Reported Jan 31
    		$0.71$0.66+7.58%Beat+73.2%
    Sep 23
    Reported Nov 2
    		$0.73$0.69+5.80%Beat+69.8%
    Jun 23
    Reported Aug 10
    		$0.67$0.63+6.35%Beat+59.5%
    Mar 23
    Reported May 4
    		$0.63$0.61+3.28%Beat+34.0%
    Dec 22
    Reported Feb 1
    		$0.41$0.43-5.29%Miss+13.9%
    Sep 22
    Reported Nov 2
    		$0.43$0.42+2.65%Beat+2.4%
    Jun 22
    Reported Aug 3
    		$0.42$0.41+2.46%Beat+0.2%
    Mar 22
    Reported Apr 29
    		$0.47$0.42+11.03%Beat+6.8%
    Dec 21
    Reported Feb 2
    		$0.36$0.36+0.95%Beat+11.1%
    Sep 21
    Reported Nov 3
    		$0.42$0.39+8.14%Beat+21.7%
    Jun 21
    Reported Aug 4
    		$0.42$0.39+7.11%Beat+16.6%
    Mar 21
    Reported May 5
    		$0.44$0.40+9.05%Beat+20.4%
    Dec 20
    Reported Feb 3
    		$0.32$0.32-0.12%Miss+18.9%
    Sep 20
    Reported Oct 30
    		$0.34$0.32+9.49%Beat+7.6%
    Jun 20
    Reported Aug 6
    		$0.36$0.36-0.19%Miss+18.8%
    Mar 20
    Reported May 6
    		$0.37$0.34+5.94%Beat+11.9%
    Dec 19
    Reported Feb 5
    		$0.27$0.28-2.71%Miss+0.9%
    Sep 19
    Reported Nov 1
    		$0.32$0.30+5.15%Beat+12.3%
    Jun 19
    Reported Aug 9
    		$0.30$0.30+0.83%Beat-7.4%
    Mar 19
    Reported May 3
    		$0.33$0.30+7.11%Beat-8.0%
    Dec 18
    Reported Feb 1
    		$0.27$0.27+0.00%Beat-4.1%
    Sep 18
    Reported Nov 1
    		$0.29$0.28+0.25%Beat-9.3%
    Jun 18
    Reported Aug 8
    		$0.33$0.33+0.52%Beat+3.2%
    Mar 18
    Reported May 2
    		$0.35$0.34+5.97%Beat+19.2%
    Dec 17
    Reported Feb 1
    		$0.28$0.29-2.93%Miss+14.1%
    Sep 17
    Reported Nov 1
    		$0.32$0.30+3.28%Beat-
    Jun 17
    Reported Aug 10
    		$0.32$0.30+5.50%Beat-
    Mar 17
    Reported May 3
    		$0.30$0.27+12.42%Beat-
    Dec 16
    Reported Feb 2
    		$0.25$0.25-1.28%Miss-

    Dividends

    Dividend Metrics

    Forward Yield4.58%
    Forward Annual Dividend$1.80
    Payout Ratio38.67%
    FrequencySemi-Annual
    Pay MonthsApr, Aug

    Growth

    3Y CAGR+29.23%
    5Y CAGR+21.57%
    NVO dividend history and ex-dividend datesRun NVO in the free DRIP calculator

    Key Metrics

    Valuation
    P/E Ratio2.68EV/EBITDA6.72x
    Price/FCF23.30xFCF Yield4.29%
    Profitability
    Profit Margin35.30%Operating Margin42.50%
    ROE59.80%ROIC33.85%
    Financial Health
    Debt/Equity0.63xInterest Coverage8.19x
    Current Ratio0.87xQuick Ratio0.66x
    Trading Statistics
    Beta0.38Avg Volume15.05M
    52-Week High$61.1152-Week Low$34.15

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$38.15
    SMA 20$38.59
    SMA 50$42.77
    SMA 200$44.36
    EMA 10$38.49
    EMA 20$39.25
    EMA 50$41.68
    EMA 200$45.21

    MACD

    Line: -1.27Signal: -1.62Hist: 0.35

    ADX

    ADX: 31.0+DI: 25.4-DI: 27.8

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down72.0
    PSAR$37.37

    Bollinger Bands

    Upper Band$41.15
    Lower Band$36.04
    %B Position1323%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    45.1

    Momentum Oscillators

    Stoch %K68.6
    Stoch %D66.3
    Williams %R-15.5
    ROC (10d)4.9%
    Momentum1.84
    CCI (20d)57.6
    MFI (14d)26.6

    Volatility Measures

    ATR (14d)$0.96(2.5%)
    StdDev (20d)1.28
    Hist Vol34.9%(Moderate)

    Volume Flow

    VWAP$39.27
    OBV-423.1M
    AD Line-13.7B
    CMF (20d)-0.038

    Volume Metrics

    Avg Vol (20d)15.3M
    Vol Ratio0.9x
    VWMA (20d)$38.70

    Pivot Points

    R3$38.91
    R2$38.67
    R1$38.39
    Pivot Point$38.15
    S1$37.87
    S2$37.63
    S3$37.35

    Advanced Oscillators

    TSI-30.07
    Ultimate Osc58.1
    KST-126.88

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$78.49B$96.82B$79.14B$74.98B$76.86B$78.09B$85.68B$71.31B$68.06B$65.35B$65.86B$58.73B
    Cost of Revenue$17.10B$13.60B$15.15B$17.90B$12.85B$12.89B$13.02B$11.31B$10.27B$9.92B$10.01B$9.71B
    Gross Profit$61.39B$83.22B$64.00B$57.07B$64.01B$65.20B$72.66B$60.00B$57.79B$55.43B$55.85B$49.02B
    Operating Expenses$34.33B$23.61B$32.26B$33.39B$30.56B$26.41B$35.92B$26.18B$31.85B$23.59B$29.08B$22.11B
    R&D$17.79B$10.28B$14.65B$15.39B$11.69B$10.31B$13.80B$9.49B$16.17B$8.61B$10.46B$8.13B
    SG&A$1.31B$1.14B$1.55B$1.88B$1.32B$1.22B$1.58B$1.38B$1.16B$1.16B$1.46B$1.26B
    Operating Income$27.06B$59.62B$31.74B$23.68B$33.45B$38.79B$36.74B$33.82B$25.93B$31.85B$26.77B$26.91B
    Interest Income$1.31B$6.05B$2.45B$1.83B$5.31B$3.42B$447.00M$1.38B$960.00M$2.15B$2.82B$1.15B
    Interest Expense$1.50B$3.50B$8.63B$5.01B$4.96B$5.18B$5.09B$821.00M$1.56B$2.07B$916.00M$2.17B
    Income Before Tax$26.88B$62.17B$34.19B$25.52B$33.80B$37.03B$35.56B$34.38B$25.33B$31.92B$27.62B$28.06B
    Income Tax Expense$5.89B$13.62B$7.29B$5.51B$7.30B$8.00B$7.33B$7.08B$5.28B$6.51B$5.66B$5.58B
    Net Income$20.99B$48.56B$26.89B$20.01B$26.50B$29.03B$28.23B$27.30B$20.05B$25.41B$21.96B$22.48B
    EBITDA$38.68B$69.21B$39.75B$33.27B$43.60B$46.05B$45.85B$37.35B$35.74B$36.91B$28.51B$32.76B
    EBIT$28.38B$65.67B$34.19B$25.52B$38.76B$42.22B$40.65B$35.20B$26.89B$33.99B$25.52B$30.23B
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    5 Buy Opportunities: GNG Research Terminal + 52-Week Low Contrarian Screen

    Screened 5,500+ stocks through GNG Research Terminal's Ultra Value Buy ranking and 52-week low contrarian overlay. Only 5 passed both tests: LRN, DDI, PFE from Ultra Value screen; ADBE...

    Glenn Ford
    •
    1/11/26
    •
    1,014
    Research Terminal, Ultra Value Buy, Systematic Screening
    Also mentions:
    ADBEDDILRNPFE

    Why I Considered Selling Novo to Buy Vici And What (and why) I Actually Did Instead

    The annual ZEUS rebalancing process is underway, with my family's financial future being decided for the next year. I recently had a very interesting discussion with Connor and Glenn about Novo and Vici and which is a potentially better investment. At first glance...

    Adam Galas
    •
    12/30/25
    •
    381
    Dividend Investing, value investing
    Also mentions:
    VICI

    News

    Inside Teva's Weltruza launch and Novo's GLP-1 strategy

    This article discusses two pharmaceutical companies: Teva and Novo. It highlights Teva's launch of Weltruza, a new schizophrenia treatment...

    Fierce Pharma•10/16/26•Somewhat-Bullish

    Factbox-Weight-loss drug developers line up to tap lucrative market as competition heats up

    The weight-loss drug market is projected to reach $100 billion in annual sales within the next decade, leading to intense competition among biotech and pharmaceutical companies. Major players like Novo Nordisk and Eli...

    KSL News•10/16/26•Neutral

    Novo Nordisk (NVO) Could Be 57% Undervalued As Buyback Puts Fair Value In Focus

    Novo Nordisk (NVO) has initiated a DKK 15 billion share repurchase program, drawing attention to its valuation. Despite recent share price declines, the company is estimated to be 57.4% undervalued...

    Simply Wall Street•10/14/26•Neutral

    Is Novo Nordisk (NYSE:NVO) A Long Term Value Opportunity Now?

    Novo Nordisk (NYSE:NVO) has experienced a significant 60% decline in share price over the past three years, prompting a re-evaluation of its current valuation against its earnings. Despite this...

    Yahoo Finance•10/14/26•Somewhat-Bullish

    Novo Nordisk's 'Future Factory' Automates Wegovy Production

    This article reports on Novo Nordisk's new "Future Factory" which is automating the production of its popular weight-loss drug...

    조선일보•10/13/26•Bullish

    NVO Valuation and Fair Value

    P/E
    2.7x
    Forward P/E
    11.8x
    EV/EBITDA
    6.7x
    P/FCF
    23.3x
    PEG
    4.3x
    P/B
    5.1x
    See GNG's fair value

    NVO Profitability: Margins, ROIC and FCF

    Gross margin
    80.6%
    Operating margin
    42.5%
    Net margin
    35.3%
    ROIC
    33.8%
    ROE
    59.8%
    FCF margin
    95.5%
    FCF yield
    4.3%

    NVO Competitors

    CompanyTicker
    Abbott LaboratoriesABT
    Pfizer IncPFE
    Gilead Sciences IncGILD
    Danaher CorporationDHR
    Amgen IncAMGN
    Intuitive Surgical IncISRG
    Thermo Fisher Scientific IncTMO
    Vertex Pharmaceuticals IncVRTX

    Sector: Healthcare

    NVO Analyst Ratings

    Consensus
    Hold
    Analysts
    14
    Strong Buy
    0
    Buy
    3
    Hold
    10
    Sell
    1
    Strong Sell
    0

    NVO Bull Case vs Bear Case

    Bull case

    • NVO earns a 33.8% return on invested capital.
    • NVO converts 95.5% of revenue into free cash flow.
    • NVO has a 35.3% net profit margin.

    NVO Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    8.0%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $4.83
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    0 up, 1 down

    NVO Dividend

    Forward yield
    4.6%
    Payout ratio
    38.7%
    3Y DPS growth
    29.2%
    5Y DPS growth
    21.6%
    Pay months
    Apr, Aug
    NVO dividend history

    Frequently Asked Questions About NVO

    What is NVO's current dividend yield?

    Novo Nordisk A/S (NVO) has a forward dividend yield of 4.58%.

    Does NVO pay dividends?

    Yes, Novo Nordisk A/S pays dividends with a forward dividend yield of 4.58%.

    What is NVO's P/E ratio?

    Novo Nordisk A/S has a price-to-earnings (P/E) ratio of 2.68.

    What is NVO's market cap?

    Novo Nordisk A/S (NVO) has a market capitalization of $167.96B with a current stock price of $39.24.

    Related stocks

    Sector: Healthcare

    All stocks starting with N

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In